CSIMarket
 


Biotechnology & Drugs Industry Profitability

Profitability Information & Trends 
  
Category:   Period:  

Biotechnology & Drugs Industry Profitability Ratios 4 Q 2018 3 Q 2018 2 Q 2018 1 Q 2018 4 Q 2017
  2018 2018 2018 2018 2017
Gross Margin 76.05 % 80.29 % 80.33 % 79.88 % 77.82 %
Gross Margin Annual (TTM) 79.39 % 80.12 % 80.41 % 80.83 % 80.94 %
Gross Margin Ranking # 8 # 3 # 2 # 3 # 12
EBITDA Margin - 38.06 % 29.95 % 33.5 % 25.16 %
EBITDA Margin Annual (TTM) 22.73 % 32.31 % 27.56 % 29.11 % 28.88 %
EBITDA Margin Ranking # 103 # 13 # 16 # 18 # 19
Operating Margin - 31.87 % 26.09 % 28.54 % 22.93 %
Operating Margin Annual (TTM) 17.9 % 27.72 % 24.87 % 26.43 % 26.55 %
Operating Margin Ranking # 99 # 9 # 14 # 9 # 23
Pre-Tax Margin - 29.91 % 22.59 % 25.48 % 19.34 %
Pre-Tax Margin Annual (TTM) 15.44 % 24.72 % 20.17 % 21.6 % 19.87 %
Pre-Tax Margin Ranking # 104 # 10 # 15 # 15 # 18
Net Margin - 24.91 % 19.38 % 23.73 % -
Net Margin Annual (TTM) 13.27 % 12.2 % 8.38 % 9.09 % 6.55 %
Net Margin Ranking # 104 # 14 # 15 # 14 # 102


Comment on the 4 Q 2018 Gross Margin within the Biotechnology & Drugs Industry

Biotechnology & Drugs Industry's Gross Margin sequentially deteriorated to 76.05 % due to increase in Cost of Sales and despite Revenue increase of 2.17 %.
Biotechnology & Drugs Industry's Gross Margin in 4 Q 2018 was lower than the Industry average.


On the trailing twelve months basis gross margin in 4 Q 2018 fell to 79.39 %.

Within Healthcare sector, Biotechnology & Drugs Industry achieved the highest gross margin. Gross margin total ranking has deteriorated compare to previous quarter from 3 to 8.

Note, Numbers include only companies who have reported earnings results. Numbers change as more businesses report financial results. See the full List.

Gross Margin Statistics
High Average Low
102.36 % 77.16 % 61.7 %
4. quarter 2013   4. quarter 2021

Gross Margin Industry Ranking
Within: No.
Healthcare Sector # 1
Overall # 8


Other Gross Margins
Compare Industry's gross margin to Sealpa's or S&P Gross profits within Biotechnology & Drugs Industry
Highest Ranking Gross Margins Lowest Ranking Gross Margins
Profitability for Sealpa's Suppliers Definiton of Gross Margin

Biotechnology & Drugs Industry EBITDA Margin Statistics

 
EBITDA Margin Statistics
High Average Low
47.91 % 26.83 % -16.18 %
4. quarter 2019   4. quarter 2021

EBITDA Margin Industry Ranking
Within: No.
Healthcare Sector # 6
Overall # 103

EBITDA Margin Comment on the 4 Q 2018 within the Biotechnology & Drugs Industry

Biotechnology & Drugs Industry recorded operating loss compare to operating income achieved in previous quarter.

On the trailing twelve months basis Ebitda Margin in 4 Q 2018 fell to 22.73 %.

Within Healthcare sector 5 other industries have achieved higher ebitda margin. Ebitda margin total ranking has deteriorated compare to previous quarter from 13 to 103.

Other EBITDA Margins
Compare Industry's EBITDA margin to Sealpa's or S&P Gross profits within Biotechnology & Drugs Industry
Highest Ranking EBITDA Margins Lowest Ranking EBITDA Margins
Profitability for Industry's Suppliers Industry Net Cash Flow Margin


Biotechnology & Drugs Industry Operating Margin Statistics

 

Operating Margin Comment on the 4 Q 2018 within the Biotechnology & Drugs Industry

Biotechnology & Drugs Industry recorded Operating Loss compare to Operating Profit achieved in previous quarter.

On the trailing twelve months basis operating margin in 4 Q 2018 fell to 17.9 %.

Within Healthcare sector 4 other industries have achieved higher operating margin. Operating margin total ranking has deteriorated compare to previous quarter from 9 to 99.



Operating Margin Statistics
High Average Low
41.3 % 21.93 % -10.83 %
4. quarter 2015   4. quarter 2018

Operating Margin Industry Ranking
Within: No.
Healthcare Sector # 5
Overall # 99

Biotechnology & Drugs Industry Pre-Tax Margin Statistics

 


Pre-Tax Margin Statistics
High Average Low
38.85 % 18.19 % -12.75 %
4. quarter 2015   4. quarter 2018

Comment on the 4 Q 2018 Pre-Tax Margin in the Biotechnology & Drugs Industry

Biotechnology & Drugs Industry recorded Pre-Tax Loss compare to Pre-Tax Income achieved in previous quarter.

On the trailing twelve months basis Pre-Tax Margin in 4 Q 2018 fell to 15.44 %.

Within Healthcare sector 5 other industries have achieved higher Pre-Tax Margin. Pre-Tax Margin total ranking has deteriorated compare to previous quarter from 10 to 104.
Pre-Tax Margin Industry Ranking
Within: No.
Healthcare Sector # 6
Overall # 104

Pre-Tax Margins
Compare Industry's pre-tax margin to Sealpa's or S&P Net profits within Biotechnology & Drugs Industry
Highest Ranking Net Margins Lowest Ranking Net Margins
Profitability for Sealpa's Competitors Industry Tax Rate


Biotechnology & Drugs Industry Net Margin Statistics

 





Net Margin Comment on the 4 Q 2018 in the Biotechnology & Drugs Industry

Biotechnology & Drugs Industry recorded Net Loss compare to Net Profit achieved in previous quarter.

On the trailing twelve months basis Net margin in 4 Q 2018 grew to 13.27 %.

Within Healthcare sector 5 other industries have achieved higher Net margin. Net margin total ranking has deteriorated compare to previous quarter from 14 to 104.

Net Margin Statistics
High Average Low
32.97 % 13.47 % -18.25 %
4. quarter 2015   4. quarter 2017
Net Margin Industry Ranking
Within: No.
Healthcare Sector # 6
Overall # 104

Other Net Margins
Compare Industry's net margin to Sealpa's or S&P Net profits within Biotechnology & Drugs Industry
Highest Ranking Net Margins Lowest Ranking Net Margins
Profitability for Sealpa's Suppliers Definiton of Net Margin





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com